fulranumab (AMG-403) - Amgen
JNJ: Pharmaceutical Business Review (J&J) - May 23, 2015 - Anticipated regulatory filing for osteoarthritis pain in 2019 
Anticipated regulatory • Pain
http://www.investor.jnj.com/webcasts-presentations.cfm
 
May 23, 2015
 
.